Elevated body mass index as a causal risk factor for symptomatic gallstone disease: A Mendelian randomization study
Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone diseas...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 58; no. 6; pp. 2133 - 2141 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.12.2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0270-9139 1527-3350 1527-3350 |
| DOI | 10.1002/hep.26563 |
Cover
| Abstract | Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow‐up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI‐increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m2) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32‐3.46) overall, 3.36 (95% CI: 2.62‐4.31) in women, and 1.51 (95% CI: 1.09‐2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0‐1 BMI‐increasing alleles was associated with a 5.2% (1.3 kg/m2) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99‐2.05) overall, 1.54 (95% CI: 1.00‐2.35) in women, and 1.19 (95% CI: 0.60‐2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m2 increase in genetically determined BMI, was 1.17 (95% CI: 0.99‐1.37) overall and 1.20 (95% CI: 1.00‐1.44) and 1.02 (95% CI: 0.90‐1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06‐1.08), 1.08 (95% CI: 1.07‐1.10), and 1.04 (95% CI: 1.02‐1.07), respectively. Conclusion: These results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women. (Hepatology 2013; 58:2133–2141) |
|---|---|
| AbstractList | Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow-up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI-increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m2) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32-3.46) overall, 3.36 (95% CI: 2.62-4.31) in women, and 1.51 (95% CI: 1.09-2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0-1 BMI-increasing alleles was associated with a 5.2% (1.3 kg/m2) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99-2.05) overall, 1.54 (95% CI: 1.00-2.35) in women, and 1.19 (95% CI: 0.60-2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m2 increase in genetically determined BMI, was 1.17 (95% CI: 0.99-1.37) overall and 1.20 (95% CI: 1.00-1.44) and 1.02 (95% CI: 0.90-1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06-1.08), 1.08 (95% CI: 1.07-1.10), and 1.04 (95% CI: 1.02-1.07), respectively. Conclusion: These results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women. (Hepatology 2013; 58:2133-2141) [PUBLICATION ABSTRACT] Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow‐up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI‐increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m2) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32‐3.46) overall, 3.36 (95% CI: 2.62‐4.31) in women, and 1.51 (95% CI: 1.09‐2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0‐1 BMI‐increasing alleles was associated with a 5.2% (1.3 kg/m2) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99‐2.05) overall, 1.54 (95% CI: 1.00‐2.35) in women, and 1.19 (95% CI: 0.60‐2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m2 increase in genetically determined BMI, was 1.17 (95% CI: 0.99‐1.37) overall and 1.20 (95% CI: 1.00‐1.44) and 1.02 (95% CI: 0.90‐1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06‐1.08), 1.08 (95% CI: 1.07‐1.10), and 1.04 (95% CI: 1.02‐1.07), respectively. Conclusion: These results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women. (Hepatology 2013; 58:2133–2141) Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow-up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI-increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m super(2)) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32-3.46) overall, 3.36 (95% CI: 2.62-4.31) in women, and 1.51 (95% CI: 1.09-2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0-1 BMI-increasing alleles was associated with a 5.2% (1.3 kg/m super(2)) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99-2.05) overall, 1.54 (95% CI: 1.00-2.35) in women, and 1.19 (95% CI: 0.60-2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m super(2) increase in genetically determined BMI, was 1.17 (95% CI: 0.99-1.37) overall and 1.20 (95% CI: 1.00-1.44) and 1.02 (95% CI: 0.90-1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06-1.08), 1.08 (95% CI: 1.07-1.10), and 1.04 (95% CI: 1.02-1.07), respectively. Conclusion: These results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women. (Hepatology 2013; 58:2133-2141) Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow-up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI-increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m(2) ) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32-3.46) overall, 3.36 (95% CI: 2.62-4.31) in women, and 1.51 (95% CI: 1.09-2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0-1 BMI-increasing alleles was associated with a 5.2% (1.3 kg/m(2) ) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99-2.05) overall, 1.54 (95% CI: 1.00-2.35) in women, and 1.19 (95% CI: 0.60-2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m(2) increase in genetically determined BMI, was 1.17 (95% CI: 0.99-1.37) overall and 1.20 (95% CI: 1.00-1.44) and 1.02 (95% CI: 0.90-1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06-1.08), 1.08 (95% CI: 1.07-1.10), and 1.04 (95% CI: 1.02-1.07), respectively.UNLABELLEDElevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow-up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI-increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m(2) ) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32-3.46) overall, 3.36 (95% CI: 2.62-4.31) in women, and 1.51 (95% CI: 1.09-2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0-1 BMI-increasing alleles was associated with a 5.2% (1.3 kg/m(2) ) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99-2.05) overall, 1.54 (95% CI: 1.00-2.35) in women, and 1.19 (95% CI: 0.60-2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m(2) increase in genetically determined BMI, was 1.17 (95% CI: 0.99-1.37) overall and 1.20 (95% CI: 1.00-1.44) and 1.02 (95% CI: 0.90-1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06-1.08), 1.08 (95% CI: 1.07-1.10), and 1.04 (95% CI: 1.02-1.07), respectively.These results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women.CONCLUSIONThese results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women. Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a Mendelian randomization approach, we studied 77,679 individuals from the general population. Of these, 4,106 developed symptomatic gallstone disease during up to 34 years of follow-up. Subjects were genotyped for three common variants known to associate with BMI: FTO(rs9939609); MC4R(rs17782313); and TMEM18(rs6548238). The number of BMI-increasing alleles was calculated for each participant. In observational analyses, mean baseline BMI was 55% (11.6 kg/m(2) ) increased in individuals in the fifth quintile versus the first quintile, similar in women and men. The corresponding multifactorially adjusted hazard ratio (HR) for symptomatic gallstone disease was 2.84 (95% confidence interval [CI]: 2.32-3.46) overall, 3.36 (95% CI: 2.62-4.31) in women, and 1.51 (95% CI: 1.09-2.11) in men (P trend: 0.001 to <0.001; P interaction: BMI*sex on risk = 0.01). In genetic analyses, carrying 6 versus 0-1 BMI-increasing alleles was associated with a 5.2% (1.3 kg/m(2) ) increase in BMI overall and with increases of 4.3% in women and 6.1% in men (all P trend: <0.001). Corresponding HRs for symptomatic gallstone disease were 1.43 (95% CI: 0.99-2.05) overall, 1.54 (95% CI: 1.00-2.35) in women, and 1.19 (95% CI: 0.60-2.38) in men (P trend = 0.007, 0.02, and 0.26, respectively; P interaction allele score*sex on risk = 0.49). The estimated causal odds ratio (OR) for symptomatic gallstone disease, by instrumental variable analysis for a 1 kg/m(2) increase in genetically determined BMI, was 1.17 (95% CI: 0.99-1.37) overall and 1.20 (95% CI: 1.00-1.44) and 1.02 (95% CI: 0.90-1.16) in women and men, respectively. Corresponding observational HRs were 1.07 (95% CI: 1.06-1.08), 1.08 (95% CI: 1.07-1.10), and 1.04 (95% CI: 1.02-1.07), respectively. These results are compatible with a causal association between elevated BMI and increased risk of symptomatic gallstone disease, which is most pronounced in women. |
| Author | Nordestgaard, Børge G. Tybjærg‐Hansen, Anne Stender, Stefan |
| Author_xml | – sequence: 1 givenname: Stefan surname: Stender fullname: Stender, Stefan organization: Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 2 givenname: Børge G. surname: Nordestgaard fullname: Nordestgaard, Børge G. organization: Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen – sequence: 3 givenname: Anne surname: Tybjærg‐Hansen fullname: Tybjærg‐Hansen, Anne organization: Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23775818$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU1v1DAURS1URKeFBX8AWWIDi7T-Suywq6qBIhXBAtbWm8QGFyce_JJC-PV4OtNNBWJheXPukX3vCTka0-gIec7ZGWdMnH9z2zPR1I18RFa8FrqSsmZHZMWEZlXLZXtMThBvGGOtEuYJORZS69pwsyK4ju4WJtfTTeoXOgAiDWPvflFACrSDGSHSHPA79dBNKVNfDi7DdkoDTKGjXyFGnMqDaB_QAbo39IJ-cMURA4w0w9inIfwubBopTnO_PCWPPUR0zw73Kfnydv358qq6_vju_eXFddUpo2XVqLZtvDHe8aaVGw7gOsd1z8AJrzdgRM29lr3i4I0WuvHec8WV5sYItTHylLzae7c5_ZgdTnYI2LkYYXRpRsu1YTVXisn_o6opnTEu64K-fIDepDmP5SM7imvVcrETvjhQ82Zwvd3mMEBe7H3zBTjfA11OiNl524XprqQpQ4iWM7vb1pZt7d22JfH6QeJe-jf2YP8Zolv-Ddqr9ad94g-nG7It |
| CODEN | HPTLD9 |
| CitedBy_id | crossref_primary_10_1016_j_gtc_2016_07_010 crossref_primary_10_1016_j_jpedsurg_2016_02_017 crossref_primary_10_1016_j_bpg_2014_07_013 crossref_primary_10_1016_j_clinsp_2024_100520 crossref_primary_10_1007_s10654_015_0081_y crossref_primary_10_1159_000515545 crossref_primary_10_3389_fnut_2024_1428488 crossref_primary_10_1016_S1957_2557_14_70838_7 crossref_primary_10_1089_lap_2019_0254 crossref_primary_10_1111_jgh_12965 crossref_primary_10_1186_s12885_024_12906_2 crossref_primary_10_1097_SLE_0000000000000278 crossref_primary_10_1007_s40471_014_0024_2 crossref_primary_10_1093_hmg_ddu328 crossref_primary_10_1097_HEP_0000000000000649 crossref_primary_10_14260_Jemds_2017_1060 crossref_primary_10_1186_s12944_020_01402_8 crossref_primary_10_1186_s12876_023_02752_0 crossref_primary_10_1111_jgh_14570 crossref_primary_10_1016_j_ypmed_2024_107942 crossref_primary_10_3748_wjg_v26_i33_4996 crossref_primary_10_3389_fsurg_2023_1097327 crossref_primary_10_5217_ir_2015_13_2_122 crossref_primary_10_1080_00325481_2018_1435129 crossref_primary_10_1007_s10654_016_0147_5 crossref_primary_10_14701_ahbps_2016_20_4_187 crossref_primary_10_1093_clinchem_hvad094 crossref_primary_10_1080_00365521_2018_1476910 crossref_primary_10_1002_hep_30861 crossref_primary_10_1016_j_jacc_2013_12_055 crossref_primary_10_1186_s12916_021_02188_x crossref_primary_10_5230_jgc_2016_16_2_98 crossref_primary_10_2188_jea_JE20220039 crossref_primary_10_4166_kjg_2020_75_5_240 crossref_primary_10_1002_oby_23561 crossref_primary_10_2478_acb_2023_0003 crossref_primary_10_1038_s41598_025_91002_2 crossref_primary_10_2174_0929867324666170530080636 crossref_primary_10_1080_00365521_2018_1481997 crossref_primary_10_1007_s11695_021_05883_z crossref_primary_10_1177_1933719116638187 crossref_primary_10_1001_jamanetworkopen_2020_18721 crossref_primary_10_1016_j_cgh_2024_01_051 crossref_primary_10_1093_eurheartj_ehy068 crossref_primary_10_1161_ATVBAHA_116_307507 crossref_primary_10_14701_ahbps_22_019 crossref_primary_10_1016_j_med_2020_05_027 crossref_primary_10_1097_MOG_0000000000000474 crossref_primary_10_3389_fendo_2023_1180903 crossref_primary_10_1186_s12876_024_03545_9 crossref_primary_10_1007_s11377_017_0221_x crossref_primary_10_21518_ms2024_385 crossref_primary_10_1002_hep_30403 crossref_primary_10_3390_jcm7110458 crossref_primary_10_1007_s12011_024_04467_z crossref_primary_10_1038_nrdp_2016_24 crossref_primary_10_1016_j_lanwpc_2024_101242 crossref_primary_10_3748_wjg_v31_i1_99960 crossref_primary_10_7759_cureus_37777 crossref_primary_10_1016_j_ajcnut_2024_07_002 crossref_primary_10_1111_joim_12577 crossref_primary_10_20517_mtod_2023_46 crossref_primary_10_4082_kjfm_2016_37_4_205 crossref_primary_10_5009_gnl15015 crossref_primary_10_1016_j_clinre_2023_102204 crossref_primary_10_1007_s00464_020_07952_3 crossref_primary_10_1111_jgh_14264 crossref_primary_10_1186_s12889_024_20512_x crossref_primary_10_1186_s43042_022_00266_0 crossref_primary_10_17476_jmbs_2022_11_2_30 crossref_primary_10_1007_s11739_024_03838_7 crossref_primary_10_1186_s12876_024_03504_4 crossref_primary_10_3389_fgene_2022_902553 crossref_primary_10_1038_s41598_020_69812_3 crossref_primary_10_3389_fmed_2023_1320735 crossref_primary_10_1016_j_cgh_2020_12_034 crossref_primary_10_1016_j_amjsurg_2021_05_008 crossref_primary_10_1159_000516418 crossref_primary_10_1136_bmjgast_2024_001417 crossref_primary_10_1002_hep_32183 crossref_primary_10_1194_jlr_S091199 crossref_primary_10_1007_s00464_021_08980_3 crossref_primary_10_1080_00365521_2017_1365166 crossref_primary_10_1111_joim_12599 crossref_primary_10_34108_eujhs_1177917 crossref_primary_10_1111_jgh_15859 crossref_primary_10_1111_jgh_16828 crossref_primary_10_1007_s00268_019_05202_9 crossref_primary_10_3389_fnut_2024_1403438 crossref_primary_10_1080_17474124_2019_1549988 crossref_primary_10_1093_ije_dyv071 crossref_primary_10_1017_S1368980020001068 crossref_primary_10_1016_j_jhep_2016_03_005 crossref_primary_10_17656_jsmc_10341 crossref_primary_10_12968_gasn_2019_17_5_32 crossref_primary_10_1371_journal_pone_0115145 crossref_primary_10_1089_lap_2014_0418 crossref_primary_10_1586_17474124_2016_1109445 crossref_primary_10_3389_fendo_2024_1367229 crossref_primary_10_3389_fnut_2024_1506477 crossref_primary_10_1016_j_hbpd_2023_11_007 crossref_primary_10_1002_hep_31537 crossref_primary_10_1016_j_cgh_2021_06_044 crossref_primary_10_1097_SGA_0000000000000235 crossref_primary_10_1007_s00595_016_1446_x |
| Cites_doi | 10.1002/hep.24046 10.1136/bmj.326.7382.219 10.1016/j.bbalip.2009.06.006 10.1038/nm1785 10.2174/1568008054064896 10.1016/S1665-2681(19)32025-3 10.1111/j.1365-2796.2007.01860.x 10.1016/S0140-6736(06)69044-2 10.1177/1536867X0300300101 10.1016/0016-5085(90)90025-V 10.1038/ng.686 10.1097/MPG.0b013e31824d256f 10.1093/jnci/djg022 10.1055/s-0031-1276645 10.1371/journal.pmed.1001212 10.1056/NEJMoa0707402 10.1002/bjs.5395 10.1136/gut.30.4.528 10.1093/ajcn/80.1.1 10.1056/NEJM199909093411101 10.1002/hep.510260401 10.1007/s00232-009-9214-0 10.1136/gut.47.1.144 10.1002/hep.20654 10.1016/j.bbrc.2010.07.075 10.1001/jama.293.3.330 10.1023/B:DDAS.0000011595.39555.c0 10.1002/sim.3034 10.1146/annurev.nu.12.070192.001503 10.1001/archinte.166.21.2369 10.1002/hep.510250623 10.1038/ng2101 |
| ContentType | Journal Article |
| Copyright | 2013 by the American Association for the Study of Liver Diseases 2013 by the American Association for the Study of Liver Diseases. |
| Copyright_xml | – notice: 2013 by the American Association for the Study of Liver Diseases – notice: 2013 by the American Association for the Study of Liver Diseases. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
| DOI | 10.1002/hep.26563 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 2141 |
| ExternalDocumentID | 3137672541 23775818 10_1002_hep_26563 HEP26563 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Chief Physician Johan Boserup and Lise Boserup's Fund – fundername: Henry Hansen and Wife's Grant – fundername: Copenhagen University Hospital – fundername: The Danish Medical Research Council funderid: 10‐083788 – fundername: The Research Fund at Rigshospitalet – fundername: The Odd Fellow Order. The funding organizations did not play a role in any of the following: design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. – fundername: Ingeborg and Leo Dannin's Grant |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX ABJNI ACZKN AFNMH AGQPQ AHQVU CITATION MEWTI WXSBR ACIJW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 AAMMB AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c4873-64996f88fe1693b1aaece17d0ae2f7ba8251f73d41af87276fff1414718824b83 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Fri Jul 11 11:35:42 EDT 2025 Thu Jul 10 21:56:14 EDT 2025 Fri Jul 25 22:57:08 EDT 2025 Thu Apr 03 06:57:26 EDT 2025 Tue Jul 01 03:33:36 EDT 2025 Thu Apr 24 23:06:27 EDT 2025 Wed Jan 22 17:02:55 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | http://doi.wiley.com/10.1002/tdm_license_1.1 2013 by the American Association for the Study of Liver Diseases. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4873-64996f88fe1693b1aaece17d0ae2f7ba8251f73d41af87276fff1414718824b83 |
| Notes | Potential conflict of interest: Nothing to report. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.26563 |
| PMID | 23775818 |
| PQID | 1461749123 |
| PQPubID | 996352 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1780514403 proquest_miscellaneous_1462370135 proquest_journals_1461749123 pubmed_primary_23775818 crossref_citationtrail_10_1002_hep_26563 crossref_primary_10_1002_hep_26563 wiley_primary_10_1002_hep_26563_HEP26563 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2013 |
| PublicationDateYYYYMMDD | 2013-12-01 |
| PublicationDate_xml | – month: 12 year: 2013 text: December 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2013 |
| Publisher | Wolters Kluwer Health, Inc |
| Publisher_xml | – name: Wolters Kluwer Health, Inc |
| References | 2007; 39 2006; 93 1990; 98 2005; 293 2000; 47 2004; 49 1997; 26 1997; 25 2007; 262 2011; 53 2008; 14 2011; 31 1999; 341 2009; 232 2005; 41 2006; 5 2003; 95 1992; 12 2012; 55 1989; 30 2010; 42 2003; 326 2008; 27 2010; 399 2005; 5 2003; 3 2008; 359 2004; 80 2006; 368 2009; 1791 2006; 166 2012; 9 Brown (10.1002/hep.26563-BIB0022|hep26563-cit-0022) 2009; 232 Zacho (10.1002/hep.26563-BIB0012|hep26563-cit-0012) 2008; 359 Leitzmann (10.1002/hep.26563-BIB0007|hep26563-cit-0007) 1999; 341 Koebnick (10.1002/hep.26563-BIB0028|hep26563-cit-0028) 2012; 55 Buch (10.1002/hep.26563-BIB0030|hep26563-cit-0030) 2007; 39 Stender (10.1002/hep.26563-BIB0011|hep26563-cit-0011) 2011; 53 Mathus-Vliegen (10.1002/hep.26563-BIB0016|hep26563-cit-0016) 2004; 49 Cirillo (10.1002/hep.26563-BIB0020|hep26563-cit-0020) 2005; 293 Baum (10.1002/hep.26563-BIB0013|hep26563-cit-0013) 2003; 3 Ståhlberg (10.1002/hep.26563-BIB0015|hep26563-cit-0015) 1997; 25 Katsika (10.1002/hep.26563-BIB0032|hep26563-cit-0032) 2005; 41 Grundy (10.1002/hep.26563-BIB0004|hep26563-cit-0004) 2004; 80 Méndez-Sánchez (10.1002/hep.26563-BIB0031|hep26563-cit-0031) 2006; 5 Lawlor (10.1002/hep.26563-BIB0008|hep26563-cit-0008) 2008; 27 Key (10.1002/hep.26563-BIB0019|hep26563-cit-0019) 2003; 95 Hayes (10.1002/hep.26563-BIB0006|hep26563-cit-0006) 1992; 12 Wang (10.1002/hep.26563-BIB0021|hep26563-cit-0021) 2009; 1791 Krawczyk (10.1002/hep.26563-BIB0029|hep26563-cit-0029) 2011; 31 Nordestgaard (10.1002/hep.26563-BIB0010|hep26563-cit-0010) 2012; 9 Attili (10.1002/hep.26563-BIB0001|hep26563-cit-0001) 1997; 26 Altman (10.1002/hep.26563-BIB0014|hep26563-cit-0014) 2003; 326 Speliotes (10.1002/hep.26563-BIB0009|hep26563-cit-0009) 2010; 42 Ogiyama (10.1002/hep.26563-BIB0024|hep26563-cit-0024) 2010; 399 Biddinger (10.1002/hep.26563-BIB0027|hep26563-cit-0027) 2008; 14 Jørgensen (10.1002/hep.26563-BIB0002|hep26563-cit-0002) 1989; 30 Portincasa (10.1002/hep.26563-BIB0005|hep26563-cit-0005) 2006; 368 Wang (10.1002/hep.26563-BIB0025|hep26563-cit-0025) 2006; 93 Vezina (10.1002/hep.26563-BIB0017|hep26563-cit-0017) 1990; 98 Méndez-Sánchez (10.1002/hep.26563-BIB0023|hep26563-cit-0023) 2005; 5 Tsai (10.1002/hep.26563-BIB0018|hep26563-cit-0018) 2006; 166 Misciagna (10.1002/hep.26563-BIB0026|hep26563-cit-0026) 2000; 47 Katsika (10.1002/hep.26563-BIB0003|hep26563-cit-0003) 2007; 262 |
| References_xml | – volume: 293 start-page: 330 year: 2005 end-page: 339 article-title: Effect of estrogen therapy on gallbladder disease publication-title: JAMA – volume: 55 start-page: 328 year: 2012 end-page: 333 article-title: Pediatric obesity and gallstone disease publication-title: J Pediatr Gastroenterol Nutr – volume: 5 start-page: 203 year: 2005 end-page: 208 article-title: Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity publication-title: Curr Drug Targets Immune Endocr Metabol Disord – volume: 12 start-page: 299 year: 1992 end-page: 326 article-title: Dietary impact on biliary lipids and gallstones publication-title: Annu Rev Nutr – volume: 3 start-page: 1 year: 2003 end-page: 31 article-title: Instrumental variables and GMM: estimation and testing publication-title: Stata J – volume: 93 start-page: 981 year: 2006 end-page: 986 article-title: Serum adiponectin levels in cholesterol and pigment cholelithiasis publication-title: Br J Surg – volume: 14 start-page: 778 year: 2008 end-page: 782 article-title: Hepatic insulin resistance directly promotes formation of cholesterol gallstones publication-title: Nat Med – volume: 98 start-page: 1000 year: 1990 end-page: 1007 article-title: Increased volume and decreased emptying of the gallbladder in large (morbidly obese, tall normal, and muscular normal) people publication-title: Gastroenterology – volume: 49 start-page: 9 year: 2004 end-page: 16 article-title: Determinants of gallbladder kinetics in obesity publication-title: Dig Dis Sci – volume: 47 start-page: 144 year: 2000 end-page: 147 article-title: Insulin and gall stones: a population case control study in southern Italy publication-title: Gut – volume: 41 start-page: 1138 year: 2005 end-page: 1143 article-title: Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs publication-title: Hepatology – volume: 25 start-page: 1447 year: 1997 end-page: 1450 article-title: Hepatic cholesterol metabolism in human obesity publication-title: Hepatology – volume: 39 start-page: 995 year: 2007 end-page: 999 article-title: A genome‐wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease publication-title: Nat Genet – volume: 262 start-page: 581 year: 2007 end-page: 587 article-title: Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study publication-title: J Intern Med – volume: 95 start-page: 1218 year: 2003 end-page: 1226 article-title: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women publication-title: J Natl Cancer Inst – volume: 399 start-page: 352 year: 2010 end-page: 358 article-title: Lack of adiponectin promotes formation of cholesterol gallstones in mice publication-title: Biochem Biophys Res Commun – volume: 30 start-page: 528 year: 1989 end-page: 534 article-title: Gall stones in a Danish population. Relation to weight, physical activity, smoking, coffee consumption, and diabetes mellitus publication-title: Gut – volume: 232 start-page: 35 year: 2009 end-page: 45 article-title: Gender differences in cholesterol nucleation in native bile: estrogen is a potential contributory factor publication-title: J Membr Biol – volume: 359 start-page: 1897 year: 2008 end-page: 1908 article-title: Genetically elevated C‐reactive protein and ischemic vascular disease publication-title: N Engl J Med – volume: 53 start-page: 640 year: 2011 end-page: 648 article-title: Sterol transporter adenosine triphosphate‐binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population publication-title: Hepatology – volume: 80 start-page: 1 year: 2004 end-page: 2 article-title: Cholesterol gallstones: a fellow traveler with metabolic syndrome? publication-title: Am J Clin Nutr – volume: 1791 start-page: 1037 year: 2009 end-page: 1047 article-title: New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation publication-title: Biochim Biophys Acta – volume: 31 start-page: 157 year: 2011 end-page: 172 article-title: Dissecting the genetic heterogeneity of gallbladder stone formation publication-title: Semin Liver Dis – volume: 26 start-page: 809 year: 1997 end-page: 818 article-title: Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis publication-title: Hepatology – volume: 341 start-page: 777 year: 1999 end-page: 784 article-title: Recreational physical activity and the risk of cholecystectomy in women publication-title: N Engl J Med – volume: 326 start-page: 219 year: 2003 article-title: Interaction revisited: the difference between two estimates publication-title: BMJ – volume: 27 start-page: 1133 year: 2008 end-page: 1163 article-title: Mendelian randomization: using genes as instruments for making causal inferences in epidemiology publication-title: Stat Med – volume: 5 start-page: 97 year: 2006 end-page: 102 article-title: Obesity‐related leptin receptor polymorphisms and gallstones disease publication-title: Ann Hepatol – volume: 42 start-page: 937 year: 2010 end-page: 948 article-title: Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index publication-title: Nat Genet – volume: 368 start-page: 230 year: 2006 end-page: 239 article-title: Cholesterol gallstone disease publication-title: Lancet – volume: 9 start-page: e1001212 year: 2012 article-title: The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach publication-title: PLoS Med – volume: 166 start-page: 2369 year: 2006 end-page: 2374 article-title: Weight cycling and risk of gallstone disease in men publication-title: Arch Intern Med – volume: 53 start-page: 640 year: 2011 ident: 10.1002/hep.26563-BIB0011|hep26563-cit-0011 article-title: Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population publication-title: Hepatology doi: 10.1002/hep.24046 – volume: 326 start-page: 219 year: 2003 ident: 10.1002/hep.26563-BIB0014|hep26563-cit-0014 article-title: Interaction revisited: the difference between two estimates publication-title: BMJ doi: 10.1136/bmj.326.7382.219 – volume: 1791 start-page: 1037 year: 2009 ident: 10.1002/hep.26563-BIB0021|hep26563-cit-0021 article-title: New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation publication-title: Biochim Biophys Acta doi: 10.1016/j.bbalip.2009.06.006 – volume: 14 start-page: 778 year: 2008 ident: 10.1002/hep.26563-BIB0027|hep26563-cit-0027 article-title: Hepatic insulin resistance directly promotes formation of cholesterol gallstones publication-title: Nat Med doi: 10.1038/nm1785 – volume: 5 start-page: 203 year: 2005 ident: 10.1002/hep.26563-BIB0023|hep26563-cit-0023 article-title: Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity publication-title: Curr Drug Targets Immune Endocr Metabol Disord doi: 10.2174/1568008054064896 – volume: 5 start-page: 97 year: 2006 ident: 10.1002/hep.26563-BIB0031|hep26563-cit-0031 article-title: Obesity-related leptin receptor polymorphisms and gallstones disease publication-title: Ann Hepatol doi: 10.1016/S1665-2681(19)32025-3 – volume: 262 start-page: 581 year: 2007 ident: 10.1002/hep.26563-BIB0003|hep26563-cit-0003 article-title: Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study publication-title: J Intern Med doi: 10.1111/j.1365-2796.2007.01860.x – volume: 368 start-page: 230 year: 2006 ident: 10.1002/hep.26563-BIB0005|hep26563-cit-0005 article-title: Cholesterol gallstone disease publication-title: Lancet doi: 10.1016/S0140-6736(06)69044-2 – volume: 3 start-page: 1 year: 2003 ident: 10.1002/hep.26563-BIB0013|hep26563-cit-0013 article-title: Instrumental variables and GMM: estimation and testing publication-title: Stata J doi: 10.1177/1536867X0300300101 – volume: 98 start-page: 1000 year: 1990 ident: 10.1002/hep.26563-BIB0017|hep26563-cit-0017 article-title: Increased volume and decreased emptying of the gallbladder in large (morbidly obese, tall normal, and muscular normal) people publication-title: Gastroenterology doi: 10.1016/0016-5085(90)90025-V – volume: 42 start-page: 937 year: 2010 ident: 10.1002/hep.26563-BIB0009|hep26563-cit-0009 article-title: Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index publication-title: Nat Genet doi: 10.1038/ng.686 – volume: 55 start-page: 328 year: 2012 ident: 10.1002/hep.26563-BIB0028|hep26563-cit-0028 article-title: Pediatric obesity and gallstone disease publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/MPG.0b013e31824d256f – volume: 95 start-page: 1218 year: 2003 ident: 10.1002/hep.26563-BIB0019|hep26563-cit-0019 article-title: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djg022 – volume: 31 start-page: 157 year: 2011 ident: 10.1002/hep.26563-BIB0029|hep26563-cit-0029 article-title: Dissecting the genetic heterogeneity of gallbladder stone formation publication-title: Semin Liver Dis doi: 10.1055/s-0031-1276645 – volume: 9 start-page: e1001212 year: 2012 ident: 10.1002/hep.26563-BIB0010|hep26563-cit-0010 article-title: The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach publication-title: PLoS Med doi: 10.1371/journal.pmed.1001212 – volume: 359 start-page: 1897 year: 2008 ident: 10.1002/hep.26563-BIB0012|hep26563-cit-0012 article-title: Genetically elevated C-reactive protein and ischemic vascular disease publication-title: N Engl J Med doi: 10.1056/NEJMoa0707402 – volume: 93 start-page: 981 year: 2006 ident: 10.1002/hep.26563-BIB0025|hep26563-cit-0025 article-title: Serum adiponectin levels in cholesterol and pigment cholelithiasis publication-title: Br J Surg doi: 10.1002/bjs.5395 – volume: 30 start-page: 528 year: 1989 ident: 10.1002/hep.26563-BIB0002|hep26563-cit-0002 article-title: Gall stones in a Danish population. Relation to weight, physical activity, smoking, coffee consumption, and diabetes mellitus publication-title: Gut doi: 10.1136/gut.30.4.528 – volume: 80 start-page: 1 year: 2004 ident: 10.1002/hep.26563-BIB0004|hep26563-cit-0004 article-title: Cholesterol gallstones: a fellow traveler with metabolic syndrome? publication-title: Am J Clin Nutr doi: 10.1093/ajcn/80.1.1 – volume: 341 start-page: 777 year: 1999 ident: 10.1002/hep.26563-BIB0007|hep26563-cit-0007 article-title: Recreational physical activity and the risk of cholecystectomy in women publication-title: N Engl J Med doi: 10.1056/NEJM199909093411101 – volume: 26 start-page: 809 year: 1997 ident: 10.1002/hep.26563-BIB0001|hep26563-cit-0001 article-title: Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis publication-title: Hepatology doi: 10.1002/hep.510260401 – volume: 232 start-page: 35 year: 2009 ident: 10.1002/hep.26563-BIB0022|hep26563-cit-0022 article-title: Gender differences in cholesterol nucleation in native bile: estrogen is a potential contributory factor publication-title: J Membr Biol doi: 10.1007/s00232-009-9214-0 – volume: 47 start-page: 144 year: 2000 ident: 10.1002/hep.26563-BIB0026|hep26563-cit-0026 article-title: Insulin and gall stones: a population case control study in southern Italy publication-title: Gut doi: 10.1136/gut.47.1.144 – volume: 41 start-page: 1138 year: 2005 ident: 10.1002/hep.26563-BIB0032|hep26563-cit-0032 article-title: Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs publication-title: Hepatology doi: 10.1002/hep.20654 – volume: 399 start-page: 352 year: 2010 ident: 10.1002/hep.26563-BIB0024|hep26563-cit-0024 article-title: Lack of adiponectin promotes formation of cholesterol gallstones in mice publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2010.07.075 – volume: 293 start-page: 330 year: 2005 ident: 10.1002/hep.26563-BIB0020|hep26563-cit-0020 article-title: Effect of estrogen therapy on gallbladder disease publication-title: JAMA doi: 10.1001/jama.293.3.330 – volume: 49 start-page: 9 year: 2004 ident: 10.1002/hep.26563-BIB0016|hep26563-cit-0016 article-title: Determinants of gallbladder kinetics in obesity publication-title: Dig Dis Sci doi: 10.1023/B:DDAS.0000011595.39555.c0 – volume: 27 start-page: 1133 year: 2008 ident: 10.1002/hep.26563-BIB0008|hep26563-cit-0008 article-title: Mendelian randomization: using genes as instruments for making causal inferences in epidemiology publication-title: Stat Med doi: 10.1002/sim.3034 – volume: 12 start-page: 299 year: 1992 ident: 10.1002/hep.26563-BIB0006|hep26563-cit-0006 article-title: Dietary impact on biliary lipids and gallstones publication-title: Annu Rev Nutr doi: 10.1146/annurev.nu.12.070192.001503 – volume: 166 start-page: 2369 year: 2006 ident: 10.1002/hep.26563-BIB0018|hep26563-cit-0018 article-title: Weight cycling and risk of gallstone disease in men publication-title: Arch Intern Med doi: 10.1001/archinte.166.21.2369 – volume: 25 start-page: 1447 year: 1997 ident: 10.1002/hep.26563-BIB0015|hep26563-cit-0015 article-title: Hepatic cholesterol metabolism in human obesity publication-title: Hepatology doi: 10.1002/hep.510250623 – volume: 39 start-page: 995 year: 2007 ident: 10.1002/hep.26563-BIB0030|hep26563-cit-0030 article-title: A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease publication-title: Nat Genet doi: 10.1038/ng2101 |
| SSID | ssj0009428 |
| Score | 2.4687712 |
| Snippet | Elevated body mass index (BMI) is associated with an increased risk of gallstone disease. Whether this reflects a causal association is unknown. Using a... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2133 |
| SubjectTerms | Aged Alleles Alpha-Ketoglutarate-Dependent Dioxygenase FTO Body Mass Index Confidence intervals Confounding Factors (Epidemiology) Denmark Female Gallstones Gallstones - genetics Hepatology Humans Male Membrane Proteins - genetics Men Middle Aged Obesity - complications Obesity - genetics Odds Ratio Proteins - genetics Random Allocation Receptor, Melanocortin, Type 4 - genetics Risk Factors Women |
| Title | Elevated body mass index as a causal risk factor for symptomatic gallstone disease: A Mendelian randomization study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.26563 https://www.ncbi.nlm.nih.gov/pubmed/23775818 https://www.proquest.com/docview/1461749123 https://www.proquest.com/docview/1462370135 https://www.proquest.com/docview/1780514403 |
| Volume | 58 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxRBEG5CDpKLz6hrHpTiwctsdnp6enrMKeiGjbJBxEAOwtBPBLMPMrtC_PVW9TxCjBHxNjDVQ_Wjpr7q6v6KsddSEG5TWVKqvExEyHyiC5snJndGllw6Yenu8PRUTs7Eh_P8fIMddndhGn6IfsONLCP-r8nAtakPrklDv_nlkCMaIabPNJPEm__-8zV1VCliXVWMukaUXS47VqERP-hb3vRFtwDmTbwaHc7xA_a1U7U5Z_J9uF6Zof35G4vjf_blIbvfAlE4albOI7bh54_ZvWmban_C6vGF_4FA1IFZuCuYIciGSK0IugYNVq9rbE4n06Gp2QMIf6G-mi1Xi0gDC5TTJ2jpoc0CvYUjmNKWO22tADpJt5i110Ah0txus7Pj8Zd3k6St0JBYDHSyRGK8JINSwROni0m19tanhRtpz0NhNN2LDUXmRKqDQqQkQwipSMkhKi6Myp6yzTnq8ZyBSqULwmmb-yCs0kYoxFZc-qAMBVED9qabq8q29OVUReOiaoiXeYWDWMVBHLBXveiy4ez4k9BuN-FVa7Y1xUEYoZXozQfsZf8aDY6yKHruF-sow7MCkXP-FxmqFEFpc_zOs2Yx9ZpgY4zRUoUdikvibhWryfhTfHjx76I7bItTwY544GaXba4u134PYdPK7KN9nHzcj1byC4fuE98 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZaxRBEC5iBPXFeLsmais--DKbnZ6enp6QlyAbVs0GkQTyIkOfCGYPnF0h_nqreo4QL8S3gake-qqpr6q6vwJ4JQXhNpUlpcrLRITMJ7qweWJyZ2TJpROW7g5Pj-XkVLw7y882YL-7C9PwQ_QBN9KM-L8mBaeA9O4la-hnvxxyhCPZNbge83MEiT5ekkeVIlZWRb9rRPnlsuMVGvHdvulVa_QLxLyKWKPJOdyCT11nm5MmX4brlRna7z_xOP7vaO7A7RaLsoNm89yFDT-_Bzembbb9PtTjc_8NsahjZuEu2AxxNovsikzXTDOr1zU2p8PprCnbwxABs_pitlwtIhMso7Q-oUvP2kTQHjtgU4q6U3SFoZ10i1l7E5RFptsHcHo4PnkzSdoiDYlFXydLJLpMMigVPNG6mFRrb31auJH2PBRG09XYUGROpDooBEsyhJCKlGyi4sKo7CFszrEfj4GpVLognLa5D8IqbYRCeMWlD8qQHzWA191iVbZlMKdCGudVw73MK5zEKk7iAF72osuGtuN3Qjvdilet5tbkCqGTVqJBH8CL_jXqHCVS9Nwv1lGGZwWC5_wvMlQsgjLn-J1HzW7qe4KN0U1LFQ4o7ok_d7GajD_Ehyf_Lvocbk5OpkfV0dvj99twi1P9jnj-Zgc2V1_X_imiqJV5FpXlBzi_FwQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZaxRBEC5ihOBLvHU1ais--DKbnZ6enh59CrrLemwIYiAPwtAngtmDzK4Qf71VPUeIF-LbwFQP1UdNfdXV_RXAcykIt6ksKVVeJiJkPtGFzROTOyNLLp2wdHd4diinx-LdSX6yBa-6uzANP0S_4UaWEf_XZOArF_YvSEO_-NWQIxrJrsBVIdFNEiL6eMEdVYpYWBXDrhGll8uOVmjE9_uml53RLwjzMmCNHmdyHT53ujYHTb4ON2sztN9_onH8z87cgN0WibKDZunchC2_uAU7szbXfhvq8an_hkjUMbN052yOKJtFbkWma6aZ1Zsam9PRdNYU7WGIf1l9Pl-tl5EHllFSn7ClZ20a6CU7YDPac6e9FYZe0i3n7T1QFnlu78DxZPzp9TRpSzQkFiOdLJEYMMmgVPBE6mJSrb31aeFG2vNQGE0XY0OROZHqoBAqyRBCKlLyiIoLo7K7sL1APe4DU6l0QThtcx-EVdoIheCKSx-UoShqAC-6uapsy19OZTROq4Z5mVc4iFUcxAE860VXDWnH74T2ugmvWrutKRDCEK1Edz6Ap_1rtDhKo-iFX26iDM8KhM75X2SoVATlzfE795rF1GuCjTFISxV2KC6JP6tYTcdH8eHBv4s-gZ2jN5Pqw9vD9w_hGqfiHfHwzR5sr882_hFCqLV5HE3lB-UrFbM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elevated+body+mass+index+as+a+causal+risk+factor+for+symptomatic+gallstone+disease%3A+a+Mendelian+randomization+study&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Stender%2C+Stefan&rft.au=Nordestgaard%2C+B%C3%B8rge+G&rft.au=Tybjaerg-Hansen%2C+Anne&rft.date=2013-12-01&rft.issn=1527-3350&rft.eissn=1527-3350&rft.volume=58&rft.issue=6&rft.spage=2133&rft_id=info:doi/10.1002%2Fhep.26563&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |